 CAMBRIDGE, Mass., April 09, 2021 GLOBE NEWSWIRE -- Surface Oncology Nasdaq: SURF, a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, will present preclinical findings supporting the companys lead product programs, SRF388 targeting IL-27 and SRF617 targeting CD39. These data will be presented as part of the American Association for Cancer Research AACR 2021 Annual Meeting, which is being held virtually April 10-15 and May 17-21, 2021. 